FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab. [electronic resource]
Producer: 20150224Description: 340 p. digitalISSN:- 1471-2407
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Cetuximab
- Colorectal Neoplasms -- drug therapy
- Disease-Free Survival
- Female
- Fluorouracil -- administration & dosage
- Humans
- Kaplan-Meier Estimate
- Leucovorin -- administration & dosage
- Male
- Middle Aged
- Mutation
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Polymorphism, Single Nucleotide
- Proportional Hazards Models
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins p21(ras)
- Receptors, IgG -- genetics
- Time Factors
- Treatment Outcome
- Young Adult
- ras Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.